These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2031454)

  • 1. Debrisoquine oxidation in Parkinson's disease.
    Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E
    Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debrisoquine hydroxylation in Parkinson's disease.
    Steiger MJ; Lledo P; Quinn NP; Marsden CD; Turner P; Jenner PG
    Acta Neurol Scand; 1992 Aug; 86(2):159-64. PubMed ID: 1414226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine hydroxylase and Parkinson's disease.
    Kondo I; Kanazawa I
    Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
    Nikolov IG; Chernozemsky IN; Idle JR
    IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C
    Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
    [No Abstract]   [Full Text] [Related]  

  • 7. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
    Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
    Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
    Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimer's disease.
    Benítez J; Barquero MS; Coria F; Molina JA; Jiménez-Jiménez FJ; Ladero JM
    J Neurol Sci; 1993 Jul; 117(1-2):8-11. PubMed ID: 8410072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA; James CA; Rogers HJ
    Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine hydroxylation in a Polish population.
    Kunicki PK; Sitkiewicz D; Pawlik A; Bielicka-Sulzyc V; Borowiecka E; Gawrońska-Szklarz B; Sterna R; Matsumoto H; Radziwoń-Zaleska M
    Eur J Clin Pharmacol; 1995; 47(6):503-5. PubMed ID: 7768252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
    Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
    Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is debrisoquine hydroxylation modified during acute viral hepatitis?
    Joanne C; Paintaud G; Bresson-Hadni S; Magnette J; Becker MC; Miguet JP; Bechtel PR
    Fundam Clin Pharmacol; 1994; 8(1):76-9. PubMed ID: 8181799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.
    Barbeau A; Cloutier T; Roy M; Plasse L; Paris S; Poirier J
    Lancet; 1985 Nov; 2(8466):1213-6. PubMed ID: 2866293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.